Watanabe S, Mizuno S, Oshima L H, Tsunematsu Y, Fujimoto J, Komiyama A
Epidemiology Division, National Cancer Center, Tokyo 104, Japan.
J Pediatr Endocrinol. 1993 Jan-Mar;6(1):99-108. doi: 10.1515/jpem.1993.6.1.99.
The number of reported cases of leukemia developing in growth hormone (GH) users worldwide has reached 31. Twelve Japanese cases are briefly reviewed; five each of AML and ALL, and one each of CML and malignant histiocytosis. The underlying diseases of these patients consisted of 8 idiopathic disease, 3 tumors and one Fanconi's anemia. Leukemia occurred during GH treatment in 9 cases and after cessation of GH in 3. The longest interval from the cessation of GH therapy was 10 years. GH administration from a younger age tended to be linked to myeloid type. Risk factors and possible mechanisms of leukemogenesis by growth hormone are discussed, and proposals for the future have been made by the Foundation for Growth Science in Japan.
全球范围内报告的生长激素（GH）使用者患白血病的病例数已达31例。本文简要回顾了12例日本病例；其中急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）各5例，慢性粒细胞白血病（CML）和恶性组织细胞增多症各1例。这些患者的基础疾病包括8例特发性疾病、3例肿瘤和1例范可尼贫血。白血病在GH治疗期间发生的有9例，在停止使用GH后发生的有3例。停止GH治疗后的最长间隔时间为10年。较年轻时开始使用GH往往与髓系类型有关。本文讨论了生长激素致白血病的危险因素和可能机制，日本生长科学基金会也提出了未来的建议。
